Trial confirms that oral semaglutide lowers cardiovascular risk in type 2 diabetes, regardless of SGLT2i use. Read more!

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

But semaglutide isn't without side effects. Some users have reported gastrointestinal issues, and a new study suggests that ...

Emergency room visits attributed to popular weight loss drugs such as Ozempic and Wegovy remain quite rare overall, but do ...

To curb hunger and help achieve weight loss, some natural alternatives to Ozempic (semaglutide) may help. See what the ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...

A groundbreaking study from the University of British Columbia has revealed a potentially disturbing side effect for those ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Semaglutide, a glucagon-like peptide-1 (GLP ... compounded drug products have not undergone FDA premarket review for safety, effectiveness, or quality. Further, neither 503A compounding pharmacies ...